{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:16:12Z","timestamp":1790172972954,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.phrs.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T10:01:38Z","timestamp":1483869698000},"page":"343-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers"],"prefix":"10.1016","volume":"117","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.01.007_bib0005","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.phrs.2017.01.007_bib0010","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"343","article-title":"Non-small cell lung cancer","author":"Bugano Diniz Gomes","year":"2016"},{"key":"10.1016\/j.phrs.2017.01.007_bib0015","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"323","article-title":"Small cell carcinoma of the lung","author":"Cascone","year":"2016"},{"key":"10.1016\/j.phrs.2017.01.007_bib0020","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"ErbB\/HER protein-tyrosine kinases: Structures and small molecule inhibitors","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0025","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-016-0365-z","article-title":"Emerging therapeutic agents for lung cancer","volume":"9","author":"Dholaria","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.phrs.2017.01.007_bib0030","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1758834015617355","article-title":"ALK inhibitors in non-small cell lung cancer: the latest evidence and developments","volume":"8","author":"Sullivan","year":"2016","journal-title":"Ther. Adv. Med. Oncol"},{"key":"10.1016\/j.phrs.2017.01.007_bib0040","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.267.5196.316-b","article-title":"Saltman DL Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"267","author":"Morris","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0045","first-page":"1567","article-title":"Hyperphosphorylation of a novel 80kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3","volume":"9","author":"Shiota","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2017.01.007_bib0050","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.01.007_bib0055","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.01.007_bib0060","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0065","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2017.01.007_bib0070","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","article-title":"ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)","volume":"14","author":"Morris","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2017.01.007_bib0075","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.embor.embor897","article-title":"A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster","volume":"4","author":"Lor\u00e9n","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2017.01.007_bib0080","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.onc.1200849","article-title":"Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system","volume":"14","author":"Iwahara","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2017.01.007_bib0085","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.modgep.2005.11.006","article-title":"Characterization of the expression of the ALK receptor tyrosine kinase in mice","volume":"6","author":"Vernersson","year":"2006","journal-title":"Gene Expr. Patterns"},{"key":"10.1016\/j.phrs.2017.01.007_bib0090","doi-asserted-by":"publisher","first-page":"e09811","DOI":"10.7554\/eLife.09811","article-title":"FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase","volume":"4","author":"Guan","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2017.01.007_bib0095","doi-asserted-by":"publisher","first-page":"15862","DOI":"10.1073\/pnas.1520099112","article-title":"Augmentor \u03b1 and \u03b2 (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions","volume":"112","author":"Reshetnyak","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.01.007_bib0100","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2017.01.007_bib0110","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0115","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0120","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2017.01.007_bib0125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0130","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/BJ20100609","article-title":"Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain","volume":"430","author":"Lee","year":"2010","journal-title":"Biochem. J"},{"key":"10.1016\/j.phrs.2017.01.007_bib0135","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0140","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2017.01.007_bib0145","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2017.01.007_bib0150","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0155","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1074\/jbc.270.14.8122","article-title":"characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain","volume":"270","author":"Wei","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0160","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nsb721","article-title":"Structure and autoregulation of the insulin-like growth factor 1 receptor kinase","volume":"8","author":"Favelyukis","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0165","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.01.007_bib0170","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1074\/jbc.M706067200","article-title":"Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase","volume":"283","author":"Tartari","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0175","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase\u2013the stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2017.01.007_bib0180","doi-asserted-by":"publisher","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.01.007_bib0185","doi-asserted-by":"publisher","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.01.007_bib0190","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0195","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0200","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0205","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2017.01.007_bib0210","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0215","doi-asserted-by":"publisher","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0220","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0225","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.01.007_bib0230","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorganic. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0235","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0240","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0245","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.01.007_bib0250","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/cam4.413","article-title":"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK","volume":"4","author":"Fontana","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.phrs.2017.01.007_bib0255","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0260","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0265","doi-asserted-by":"publisher","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.phrs.2017.01.007_bib0270","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"Dagogo-Jack","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0275","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer. Discov"},{"key":"10.1016\/j.phrs.2017.01.007_bib0280","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2017.01.007_bib0285","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0290","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bmc.2011.12.021","article-title":"Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)","volume":"20","author":"Kinoshita","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0295","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0300","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0305","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0310","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2017.01.007_bib0315","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0320","article-title":"Drug resistance in ALK-positive non-small cell lung cancer patients","author":"Qian","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0325","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0330","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0335","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the gatekeeper door: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.01.007_bib0340","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2017.01.007_bib0345","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2017.01.007_bib0350","article-title":"Exploring the benefit\/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients","author":"Kurzrock","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.01.007_bib0355","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody therapeutics in cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.01.007_bib0360","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0365","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","author":"Fischer","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"1923","key":"10.1016\/j.phrs.2017.01.007_bib0370","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.01.007_bib0375","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening\u2014a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0380","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2125.1992.tb04051.x","article-title":"New drug treatments for HIV infection and AIDS. a review following the seventh international conference on AIDS, Florence 16\u201321 June 1991","volume":"33","author":"Venning","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0385","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.coviro.2013.03.014","article-title":"HIV-1 reverse transcriptase and antiviral drug resistance Part 2","volume":"3","author":"Das","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.phrs.2017.01.007_bib0390","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phrs.2016.05.007","article-title":"Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics","volume":"110","author":"Adah","year":"2016","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817300166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817300166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T04:23:41Z","timestamp":1568694221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817300166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":78,"alternative-id":["S1043661817300166"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.01.007","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}